Ionis Pharmaceuticals, Inc. Impairment of Intangible Assets, Finite-lived
Ionis Pharmaceuticals, Inc. (IONS) reported Impairment of Intangible Assets, Finite-lived of $481.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. impairment of intangible assets, finite-lived for the quarter ending 2026-06-30 was $441.00K, a 86.86% increase year-over-year.
- Ionis Pharmaceuticals, Inc. impairment of intangible assets, finite-lived for the quarter ending 2026-03-31 was $40.00K, a 34.43% decline year-over-year.
- Ionis Pharmaceuticals, Inc. impairment of intangible assets, finite-lived for the quarter ending 2025-12-31 was $4.63M, a 128.82% increase year-over-year.
- Ionis Pharmaceuticals, Inc. impairment of intangible assets, finite-lived for the quarter ending 2025-09-30 was -$3.94M, a 735.48% decline year-over-year.
- Ionis Pharmaceuticals, Inc. impairment of intangible assets, finite-lived for fiscal 2025 was $986.00K, a 67.48% decline from fiscal 2024.
- Ionis Pharmaceuticals, Inc. impairment of intangible assets, finite-lived for fiscal 2024 was $3.03M, a 66.41% increase from fiscal 2023.
- Ionis Pharmaceuticals, Inc. impairment of intangible assets, finite-lived for fiscal 2023 was $1.82M, a 10.25% decline from fiscal 2022.
- Ionis Pharmaceuticals, Inc. impairment of intangible assets, finite-lived for fiscal 2022 was $2.03M, a 25.01% decline from fiscal 2021.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 6 month as first filed | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 9 month as first filed | Impairment of Intangible Assets, Finite-lived 12 month | Impairment of Intangible Assets, Finite-lived 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $441.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $481.00K 10-Q · filed 2026-07-29 | $5.11M derived: sum of 3 quarters · filed 2026-07-29 | $1.17M derived: sum of 4 quarters · filed 2026-07-29 | |||
| 2026-03-31 | $40.00K 10-Q · filed 2026-04-29 | $4.67M derived: sum of 2 quarters · filed 2026-04-29 | $729.00K derived: sum of 3 quarters · filed 2026-04-29 | $965.00K derived: sum of 4 quarters · filed 2026-07-29 | |||
| 2025-12-31 | $4.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $689.00K derived: sum of 2 quarters · filed 2026-02-26 | $925.00K derived: sum of 3 quarters · filed 2026-07-29 | $986.00K 10-K · filed 2026-02-26 | |||
| 2025-09-30 | -$3.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$3.70M derived: sum of 2 quarters · filed 2026-07-29 | -$3.64M 10-Q · filed 2025-10-29 | -$1.62M derived: sum of 4 quarters · filed 2026-07-29 | |||
| 2025-06-30 | $236.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $297.00K 10-Q · filed 2026-07-29 | $2.32M derived: sum of 3 quarters · filed 2026-07-29 | $2.94M derived: sum of 4 quarters · filed 2026-07-29 | |||
| 2025-03-31 | $61.00K 10-Q · filed 2026-04-29 | $2.08M derived: sum of 2 quarters · filed 2026-04-29 | $2.70M derived: sum of 3 quarters · filed 2026-04-29 | $2.96M derived: sum of 4 quarters · filed 2026-04-29 | |||
| 2024-12-31 | $2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.64M derived: sum of 2 quarters · filed 2026-02-26 | $2.90M derived: sum of 3 quarters · filed 2026-02-26 | $3.03M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $620.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $876.00K derived: sum of 2 quarters · filed 2025-10-29 | $1.01M 10-Q · filed 2025-10-29 | $895.00K 10-Q · filed 2024-11-06 | $1.98M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | $256.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $389.00K 10-Q · filed 2025-07-30 | $1.36M derived: sum of 3 quarters · filed 2026-02-26 | $1.44M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | $133.00K 10-Q · filed 2025-04-30 | $1.11M derived: sum of 2 quarters · filed 2026-02-26 | $1.18M derived: sum of 3 quarters · filed 2026-02-26 | $1.51M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $973.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.05M derived: sum of 2 quarters · filed 2026-02-26 | $1.38M derived: sum of 3 quarters · filed 2026-02-26 | $1.82M 10-K · filed 2026-02-26 | $1.66M 10-K · filed 2024-02-21 | ||
| 2023-09-30 | $74.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $404.00K derived: sum of 2 quarters · filed 2024-11-06 | $849.00K 10-Q · filed 2024-11-06 | $1.72M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-06-30 | $330.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $775.00K 10-Q · filed 2024-08-01 | $570.00K 10-Q · filed 2023-08-09 | $1.65M derived: sum of 3 quarters · filed 2025-02-19 | $1.85M derived: sum of 4 quarters · filed 2025-02-19 | ||
| 2023-03-31 | $445.00K 10-Q · filed 2024-05-07 | $1.32M derived: sum of 2 quarters · filed 2025-02-19 | $1.52M derived: sum of 3 quarters · filed 2025-02-19 | $2.37M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2022-12-31 | $875.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $1.08M derived: sum of 2 quarters · filed 2025-02-19 | $1.92M derived: sum of 3 quarters · filed 2025-02-19 | $2.03M 10-K · filed 2025-02-19 | |||
| 2022-09-30 | $204.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.04M derived: sum of 2 quarters · filed 2023-11-02 | $1.16M 10-Q · filed 2023-11-02 | $2.71M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-06-30 | $841.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $951.00K 10-Q · filed 2023-08-09 | $2.51M derived: sum of 3 quarters · filed 2024-02-21 | $2.83M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-03-31 | $110.00K 10-Q · filed 2023-05-03 | $1.67M derived: sum of 2 quarters · filed 2024-02-21 | $1.99M derived: sum of 3 quarters · filed 2024-02-21 | $2.60M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2021-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $1.88M derived: sum of 2 quarters · filed 2024-02-21 | $2.49M derived: sum of 3 quarters · filed 2024-02-21 | $2.71M 10-K · filed 2024-02-21 | |||
| 2021-09-30 | $323.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $929.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.15M 10-Q · filed 2022-11-09 | $2.48M derived: sum of 4 quarters · filed 2023-02-22 | |||
| 2021-06-30 | $606.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $827.00K 10-Q · filed 2022-08-09 | $2.16M derived: sum of 3 quarters · filed 2023-02-22 | $2.58M derived: sum of 4 quarters · filed 2023-02-22 | |||
| 2021-03-31 | $221.00K 10-Q · filed 2022-05-04 | $1.55M derived: sum of 2 quarters · filed 2023-02-22 | $1.98M derived: sum of 3 quarters · filed 2023-02-22 | $2.01M derived: sum of 4 quarters · filed 2023-02-22 | |||
| 2020-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $1.76M derived: sum of 2 quarters · filed 2023-02-22 | $1.79M derived: sum of 3 quarters · filed 2023-02-22 | $1.95M 10-K · filed 2023-02-22 | |||
| 2020-09-30 | $424.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $457.00K derived: sum of 2 quarters · filed 2021-11-03 | $616.00K 10-Q · filed 2021-11-03 | ||||
| 2020-06-30 | $33.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $192.00K 10-Q · filed 2021-08-04 | |||||
| 2020-03-31 | $159.00K 10-Q · filed 2021-05-05 | ||||||
| 2019-12-31 | $2.23M 10-K · filed 2022-02-25 | ||||||
| 2018-12-31 | $802.00K 10-K · filed 2021-02-24 | ||||||
| 2015-12-31 | $1.90M 10-K · filed 2016-02-26 | ||||||
| 2014-12-31 | $1.30M 10-K · filed 2016-02-26 | ||||||
| 2013-12-31 | $5.96M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $6.13M derived: sum of 2 quarters · filed 2016-02-26 | $6.40M 10-K · filed 2016-02-26 | ||||
| 2013-09-30 | $166.00K 10-Q · filed 2013-11-05 | $441.00K 10-Q · filed 2013-11-05 | |||||
| 2013-06-30 | $275.00K 10-Q · filed 2013-08-06 | ||||||
| 2012-09-30 | $376.00K 10-Q · filed 2013-11-05 | $664.00K 10-Q · filed 2013-11-05 | |||||
| 2012-06-30 | $288.00K 10-Q · filed 2013-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |